Temasek Invests in Series B Round for AccuraGen

Sovereign wealth funds continue tactically investing in the pharmaceutical sector. Menlo Park-based AccuraGen, a liquid biopsy technology startup, raised US$ 40 million in a Series B round. [ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]

Contact the writer or creator of this article or page.
Questions or comments: support(at)swfinstitute(dot)org
Follow on Twitter at @swfinstitute and @sovereignfunds
Learn, Attend and Network: Institutional Investor Events and Summits
Go Back: HOME: Sovereign Wealth Fund Institute

institutional investor investment mandates